Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

appeared in the February 3, 2011 issue.  

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and fluoroquinolones), older age (over 65) and exposure to emerging hyper-virulent strains (BI/NAP1/027, 078, 001) of C. difficile. The rise in incidence of CDI, along with high rates of both treatment failures and recurrences with current therapies has resulted in greater awareness and concern about CDI among medical professionals and public health officials. Advancing age is one of the most significant risk factors for CDI and with the 65-plus population growing every year in the US, the incidence of CDI has the potential to increase in hospitals and long-term care facilities. You may learn more about CDI at www.cdiinfo.org, a website of Optimer.

Abo
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  Decision Resources, one of the ... pharmaceutical and healthcare issues, finds that the ... efficacy endpoints, including overall survival and time ... over surveyed U.S. and European oncologists, prescribing ... breast cancer. The two novel emerging therapies ...
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 ... the design and manufacture of wireless personal healthcare ... to broaden its reach, announcing the release of ... of wireless blood pressure monitors and scales: the ... Tracker. (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...
(Date:5/21/2013)... , May 21, 2013 BioElectronics Corp. ... consumer electronic devices, announced that CEO, ... to the FDA,s Medical Advisory Committee, Orthopedic and ... products for over the counter sales. ... its medical device classification schema," Whelan said.  "While ...
Breaking Medicine Technology:Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer 2iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... more ... study, DURANGO, Colo. and NEW HAVEN, Conn., ... innovation networks, today announced,that the company is providing ... Applied Spine,s Stabilimax NZ(R) Dynamic Spine,Stabilization System. Stabilimax ...
... 18 Worldwide markets of,approved EGFr/HEr2 inhibitors grew by ... more than $3.2 billion, exceeding total sales reported in,2005. ... for these drugs and fueling continued rapid market growth. ... 50 novel,agents targeting this pathway are in development. ...
Cached Medicine Technology:Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System 2Syndicom SpineConnect Web Platform Chosen for Applied Spine's Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System 3
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
(Date:5/21/2013)... The Brazilian funding agency for scientific and technological research ... of So Paulo, announced an investment estimated in US$ ... Centers (RIDCs) for a period of up to eleven ... and 7. , Funding for the 17 RIDCs ... funding faculty, technicians, support personnel, and infrastructure). Host institutions ...
(Date:5/21/2013)... 21, 2013 Today, Zane Benefits, Inc. ... FSA accounts. Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... , According to Zane Benefits’ website, the Affordable Care ... into law in 2010 and impacts many areas of ...
(Date:5/21/2013)... While North Carolina is synonymous with ... guides. Brunswick Plantation & Golf Resort is synonymous with ... to 27 holes of "Top10" championship golf. , ... knowing the Top 10 from an industry ... overwhelming task of selecting the course to play. Guests ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... YORK, Sept. 26 The American Liver Foundation ... improving the,quality of life for the 30 million ... has been named to become the next President ... 5, 2007. Mr. Smith,a senior nonprofit executive with ...
... Today, at the annual,conference of the Colorado ... along with the Colorado Springs Police Department,announced the ... raise awareness and reduce demand for the highly ... was created by the Partnership, and is,currently operating ...
... researchers has found that adolescents may suffer from severe ... diagnosed with cancer and that parents tend to underestimate ... life experiences that can be so stressful that it ... develop post-traumatic stress symptoms (PTSS) go on to develop ...
... YORK, Sept. 26 Paramount Acquisition,Corp. (OTC Bulletin Board: ... its board of directors has established the close of,business ... determine Paramount,s,stockholders who will be entitled to receive notice ... stockholders to be held to consider and vote,on the ...
... TIGroup, Inc. (OTC,Bulletin Board: TISG), a California-based financial ... surgical centers (ASCs) and,other businesses designed to deliver ... named Dennis M. Smith as the company,s,chief financial ... the company,s board,since 2001. Smith was most ...
... Outside North America in Deal Valued at up ... to ... Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP ) and,Nycomed ... licenses to Nycomed the rights to develop and commercialize,GATTEX(TM) (teduglutide) ...
Cached Medicine News:Health News:The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer 2Health News:Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement 2Health News:Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement 3Health News:Study finds post-traumatic stress symptoms in adolescent children of cancer patients 2Health News:Study finds post-traumatic stress symptoms in adolescent children of cancer patients 3Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 4Health News:TIGroup Names Dennis M. Smith as Chief Financial Officer 2Health News:TIGroup Names Dennis M. Smith as Chief Financial Officer 3Health News:TIGroup Names Dennis M. Smith as Chief Financial Officer 4Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: